Investors
Welcome to the iCAD Investors page.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.
2024 Investor Deck
Q3 Earnings Call
iCAD will host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024.
Toll Free: 877-545-0320
International: 973-528-0002
Participant Access Code: 509249
Sign up to receive Investor Alerts.
Subscribe to receive investor alerts from iCAD, Inc.
Press Releases
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
NASHUA, N.H., March 11, 2025 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time…
iCAD and RamSoft Announce Partnership to Deliver ProFound AI-Powered Mammography Solutions Across North America
NASHUA, NH, and TORONTO, CANADA, March 05, 2025 — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across…
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
NASHUA, NH, and CHICAGO, IL, February 26, 2025 — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection….